Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx is a strong player in the healthcare market, with a unique intelligent technology platform that connects healthcare providers and their patients. Despite some macro headwinds and execution issues with a large client, OptimizeRx is poised for strong revenue growth in the high teens/low twenties, driven by the adoption of its AI-enabled DAAP, mid-tier and MedTech clients, and a transition to subscription-based revenue. While the FY26 guidance was lowered due to the client issue, there is potential for stronger financial performance in FY27.

Bears say

OptimizeRx is exposed to the impact of reductions in pharmareimbursement and budget restraints in biopharma, hindering its primarily life sciences-driven revenue. Any changes in regulations surrounding the marketing of prescription drugs could have negative consequences for its business model. Additionally, a recent CFO transition raises concerns about financial stability in the near future.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.